Zydus (via its relevant life sciences business) is set to acquire Assertio, a U.S. firm, in a deal valued at $166 million (about ₹1,570 crore). Both outlets report that the transaction is structured as a merger and that Zydus will begin a tender offer to acquire all outstanding shares of Assertio common stock, in line with the terms of the merger agreement.
The acquisition is intended to expand Zydus’s operations in the United States, giving it access to a branded-drugs commercial platform. Sources also describe the move as strengthening Zydus’s specialty pharmaceutical footprint, particularly in therapeutic areas including pain and oncology. The reported rationale centers on leveraging Assertio’s U.S. presence and product and commercial capabilities to grow Zydus’s business in these segments.
The announcements focus on deal value, the tender offer for all shares, and the strategic fit around specialty and branded offerings in the U.S. market. Details on closing timing or regulatory approvals are not included in the excerpts provided.
